Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study

Autor: Tina Maluso, Regina A. Swift, Jason D. Nosrati, Eric Wirtschafter, Michael Ghermezi, Aleksandra Vidisheva, James R. Berenson, Sean Bujarski, Tanya M. Spektor, Kyle Udd, Zachary Gross, Benjamin Eades, Gary Cecchi, Ashkon Rahbari
Rok vydání: 2018
Předmět:
Zdroj: European Journal of Haematology. 100:621-623
ISSN: 0902-4441
DOI: 10.1111/ejh.13058
Popis: Objective To evaluate the efficacy and safety of elotuzumab and dexamethasone (Ed) for relapsed or refractory multiple myeloma (RRMM) patients. Method This retrospective study evaluated the efficacy and safety of (Ed) treatment for 21 RRMM patients, 11 of whom were considered lenalidomide-refractory, and all of whom had progressed on at least 1 prior steroid-containing regimen. We also evaluated the efficacy of adding lenalidomide to a subset of patients following progression from Ed. Results The overall response rate (ORR) and clinical benefit rate (CBR) of Ed were 10% and 19%, respectively. An additional 52% of patients demonstrated stable disease as their best response. The median PFS was 1.8 months on Ed for all patients. Fifteen patients received ERd following progression on Ed, and 60% of these patients were lenalidomide-refractory. The ORR and CBR were 20% and 33%, respectively, and the median PFS was 3.4 months. Conclusion Our results suggest that some patients can benefit from Ed without an accompanying immunomodulatory agent and that efficacy can be achieved with the addition of lenalidomide at the time of progression. No new safety signals were detected, except for thrombocytopenia in 1 patient on Ed. This article is protected by copyright. All rights reserved.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje